Caspase

Histogen Reports First Quarter 2023 Results and Provides Business Update

Retrieved on: 
Thursday, May 11, 2023
Mouse, CA-MRSA, Emricasan, Infection, COVID-19, Caspase, Enzyme, COVID, Inflammation, Staphylococcus, Staphylococcus aureus, ABSSSI, Doxycycline, Fungal infection, Patient, Risk, SAN, Apoptosis, Immune system, USA300, Toxicology, Safety, Pharmaceutical industry, Vaccine

SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today reported financial results for the first quarter ended March 31, 2023, and provided an update on its pipeline and other corporate developments.

Key Points: 
  • Exclusive Intellectual Property License Agreement with Johns Hopkins – In April 2023, we signed an exclusive license agreement with Johns Hopkins University.
  • Steven J. Mento Ph.D. appointed President and CEO – In March 2023, Dr. Mento was appointed President and CEO.
  • First Quarter 2023 Financial Highlights: Three Months Ended March 31, 2023 and 2022
    Revenues for the three months ended March 31, 2023 and 2022, we recognized license revenue of $5 thousand and $3.8 million, respectively.
  • Research and development expenses for the three months ended March 31, 2023 and 2022 were $1.0 million and $1.9 million, respectively.

Histogen Reports Year-End 2022 Results and Provides Business Update

Retrieved on: 
Thursday, March 9, 2023
Methicillin, Trial of the century, IND, Conatus, Acquisition, HST, Medication, Pfizer, Enzyme, ABSSSI, Knee, SAN, Mortgage assumption, Research, NSF, Patient, Extracellular matrix, CCM, Interim, Staphylococcus aureus, EVP, Apoptosis, Cartilage, CSO, Inflammation, COVID-19, Insurance, Caspase, Toxicology, Sale, MRSA, Safety, Pharmaceutical industry, Cryptocurrency, Allergan

Twelve Months Ended December 31, 2022 and 2021

Key Points: 
  • Twelve Months Ended December 31, 2022 and 2021
    For the years ended December 31, 2022 and 2021, we recognized license revenues of $3.8 million and $27 thousand, respectively.
  • For the years ended December 31, 2022 and 2021, we recognized grant revenue of $0 and $0.1 million, respectively.
  • Research and development expenses for the years ended December 31, 2022 and 2021 were $5.0 million and $8.5 million, respectively.
  • General and administrative expenses for the years ended December 31, 2022 and 2021 were $9.4 million and $7.8 million, respectively.

Amerimmune LLC Maintains Intellectual Property on the COVID-19 Related Use of Caspase Inhibitors as a Result of Histogen Inc. Led Arbitration

Retrieved on: 
Wednesday, January 18, 2023
Health, Infectious Diseases, COVID-19, Research, Science, Pharmaceutical, Biotechnology, Emricasan, Peace and Collaborative Development Network, Immunity, CDCA, Safety, Videophilia (and Other Viral Syndromes), Organization, Immune system, Patient, HIV disease progression rates, Caspase, Commercialization, Pharmaceutical industry, COVID19

Amerimmune LLC had a discovery early in 2020, showing elevated caspase molecules in peripheral blood immune cells of COVID19 patients.

Key Points: 
  • Amerimmune LLC had a discovery early in 2020, showing elevated caspase molecules in peripheral blood immune cells of COVID19 patients.
  • Caspase molecules help build immunity to pathogens, but can also have detrimental effects on the immune system.
  • The scientists at Amerimmune had the idea that a stronger and prolonged caspase activity can cause the poor outcomes seen in some patients with COVID-19.
  • Histogen Inc. filed for arbitration to terminate the Collaborative Development and Commercialization Agreement (CDCA) between Amerimmune and Histogen Inc.

Phosplatin Therapeutics Reports on PT-112's Selective Effects and Immunogenic Cell Death in Human Prostate Cancer Cell Models at the AACR Annual Meeting 2022

Retrieved on: 
Monday, April 11, 2022
Mitochondrion, Cancer, Therapy, Family, Large-cell lung carcinoma, Congress, DNA, Lung, Merck Group, Reactive oxygen species, Cell death, Trial of the century, CRADA, ICD, Growth, Organelle, AACR, Immunogenic cell death, Doctor of Philosophy, Caspase, Research, B cell, Tumor microenvironment, Development of the human body, Damage-associated molecular pattern, NSCLC, Multiple myeloma, Safety, DAMP, Prostate cancer, Merck Serono, CST, Thymoma, American Academy, Autophagy, César Award for Best Poster, ESMO, ASH, Necroptosis, NCI, PD-L1, University, Patient, Pharmaceutical industry, Vaccine, Platinum

"The result of this study provides a better understanding of PT-112's mechanism of action, in a manner that is linked to its established immunogenic cell death effects.

Key Points: 
  • "The result of this study provides a better understanding of PT-112's mechanism of action, in a manner that is linked to its established immunogenic cell death effects.
  • Sensitivity to PT-112 was assessed in human prostate cancer cell lines and the non-tumorigenic prostate cell line RWPE-1.
  • Key findings of the study included the following:
    PT-112 caused growth inhibition and cancer cell death without affecting healthy RWPE-1 cells.
  • Caspase inhibition reduced PT-112-induced cell death, with more mild effects seen with necroptosis inhibition, suggesting that cell death is primarily apoptotic.

Bellicum Enters License Agreement with UNC Lineberger and Mass General for Use of CaspaCIDe® Safety Switch

Retrieved on: 
Monday, June 28, 2021
Branches of biology, Caspases, Caspase-9, Chimeric antigen receptor T cell, Caspase

This agreement with UNC Lineberger and Mass General covers four CAR-T programs incorporating Bellicums technology currently in development, two of which are owned by UNC Lineberger and two of which are co-owned by both institutions.

Key Points: 
  • This agreement with UNC Lineberger and Mass General covers four CAR-T programs incorporating Bellicums technology currently in development, two of which are owned by UNC Lineberger and two of which are co-owned by both institutions.
  • We believe the agreement reflects the potential value of our switch technology, which may enhance the benefit/risk profile of cell therapies.
  • CaspaCIDe (inducible caspase-9, or iC9) is Bellicums chemical induction of dimerization (CID) safety switch technology designated to eliminate cells in the event of toxicity.
  • Any forward-looking statements that Bellicum makes in this press release speak only as of the date of this press release.

Severe Side Effects of Leukemia CAR-T Immunotherapy Can Be Turned off With a Specially Engineered Safety Switch

Retrieved on: 
Thursday, March 4, 2021
Science, Research, Pharmaceutical, Oncology, Health, University, Education, Clinical trials, Branches of biology, Clinical medicine, Medicine, Cancer immunotherapy, Caspases, Programmed cell death, Caspase-9, Chimeric antigen receptor T cell, Immunotherapy, Caspase

It demonstrates a proof-of-principle for possible expanded use of CAR-T immunotherapy paired with the safety switch.

Key Points: 
  • It demonstrates a proof-of-principle for possible expanded use of CAR-T immunotherapy paired with the safety switch.
  • So UNC Lineberger researchers engineered T-cells to include a safety switch, called inducible caspase-9, or iC9, that can be activated if toxic side effects develop.
  • Administration of the drug rimiducid triggers the switch to activate the expression of caspase-9, potentially leading to reduced severe side effects from the CAR-T therapy.
  • Her clinicians quickly reduced the severity of the side effects by administering the drug rimiducid to activate the iC9 safety switch.

Bellicum Announces First Reported Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity

Retrieved on: 
Thursday, March 4, 2021
Branches of biology, Medical specialties, Clinical medicine, Immune system, Caspases, T cells, Chimeric antigen receptor T cell, Leukemia, Lymphoma, Caspase-9, Caspase

This publication marked the first reported clinical use of the iC9 safety switch to mitigate a severe CAR-T-mediated adverse event refractory to standard of care treatment.

Key Points: 
  • This publication marked the first reported clinical use of the iC9 safety switch to mitigate a severe CAR-T-mediated adverse event refractory to standard of care treatment.
  • CaspaCIDe (inducible caspase-9, or iC9) is Bellicums chemical induction of dimerization (CID) safety switch technology designated to eliminate cells in the event of toxicity.
  • The companys next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies.
  • Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential for the CaspaCIDe safety switch and rimiducid to improve safety of cell therapies; and the potential useful life of the CaspaCIDe safety switch.

Outlook on the Apoptosis Assay Global Market to 2028 - by Product, Technique, Assay Type, End-use and Region - ResearchAndMarkets.com

Retrieved on: 
Monday, February 22, 2021
Pharmaceutical, Health, Oncology, Other Health, Branches of biology, Biology, Programmed cell death, Cell biology, Cell signaling, Laboratory techniques, Apoptosis, Assay, DNA fragmentation, Fragmentation, Caspase, Mitochondrion

The global apoptosis assay market size is expected to reach USD 8.20 billion by 2028, according to the study.

Key Points: 
  • The global apoptosis assay market size is expected to reach USD 8.20 billion by 2028, according to the study.
  • This report gives a detailed insight into current market dynamics and provides analysis on future market growth.
  • The global apoptosis assay industry is fragmented based on product, technique, assay type, end-use, and region.
  • Based on the assay type, the apoptosis test market is classified as Caspase, DNA Fragmentation, Cell Permeability, and Mitochondrial.

AC Immune Reports Progress for Therapeutic Programs Targeting the NLRP3 Inflammasome Pathway

Retrieved on: 
Friday, January 29, 2021
Branches of biology, Programmed cell death, NLRP3, Inflammasome, Caspase, NLRP, CARD domain, Apoptosis, Thirumala-Devi Kanneganti, Dapansutrile

AC immune is currently evaluating potential lead compounds for further in vivo efficacy and CNS delivery.

Key Points: 
  • AC immune is currently evaluating potential lead compounds for further in vivo efficacy and CNS delivery.
  • A critical component of the NLRP3 pathway is ASC (apoptosis-associated speck-like protein containing a C-terminal caspase recruitment domain), which is released by immune cells following NLRP3 inflammasome activation.
  • Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: Accelerating our complementary programs targeting the NLRP3 pathway intra- and extracellularly is a core element of our growth execution strategy in 2021 and beyond.
  • Advancing multiple high-value assets targeting the inflammasome pathway further demonstrates AC Immunes ambition to shape a comprehensive pipeline addressing key targets in neurodegeneration.

Apoptosis Assay Market Size Worth $7.5 Billion By 2027 | CAGR: 7.6%: Grand View Research, Inc.

Retrieved on: 
Wednesday, November 4, 2020
Branches of biology, Biology, Cell biology, Apoptosis, Cellular senescence, Biochemistry, Mitochondria, Assay, Caspase, Bcl-2, Programmed cell death, Cell death

Also, high demand for caspase activity assays along with Bcl-2 protein family across pharmaceutical companies for apoptosis detection has been observed in recent years.

Key Points: 
  • Also, high demand for caspase activity assays along with Bcl-2 protein family across pharmaceutical companies for apoptosis detection has been observed in recent years.
  • Whereas, stringent regulations with respect to the approval of cell-potency assays are ensuring successful uptake of market products launched.
  • In addition, the growing significance of programmed cell death or apoptosis to treat chronic diseases is driving the segment growth.
  • Grand View Research has segmented the global apoptosis assay market on the basis of product, technique, assay type, end-use, and region:
    Apoptosis Assay Product Outlook (Revenue, USD Million, 2016 - 2027)